Prostate cancer: understanding why.

Androgen receptor signaling regulates DNA repair in prostate cancers. Cancer Discov (2013) 2.15

A hormone-DNA repair circuit governs the response to genotoxic insult. Cancer Discov (2013) 1.97

Interferon-gamma induces Fas trafficking and sensitization to apoptosis in vascular smooth muscle cells via a PI3K- and Akt-dependent mechanism. Am J Pathol (2006) 0.99

Glioblastoma: The histones have it. Nat Rev Cancer (2013) 0.97

Melanoma: Horses for courses. Nat Rev Cancer (2013) 0.96

Epigenetics. Going places with BANCR. Nat Rev Cancer (2012) 0.89

Metabolism: unmasking an oncometabolite. Nat Rev Cancer (2012) 0.85

Rapamycin inhibits human in stent restenosis vascular smooth muscle cells independently of pRB phosphorylation and p53. Cardiovasc Res (2005) 0.84

Leukaemia: MLL makes friends and influences. Nat Rev Cancer (2010) 0.83

Regulatory RNA: layer by layer. Nat Rev Genet (2011) 0.83

Cancer: Small losses, big gains with microRNAs. Nat Rev Genet (2010) 0.83

Differential cyclin E expression in human in-stent stenosis smooth muscle cells identifies targets for selective anti-restenosis therapy. Cardiovasc Res (2003) 0.83

Tumorigenesis: oncogene detox programme. Nat Rev Cancer (2011) 0.82

Tumorigenesis: All together now. Nat Rev Cancer (2013) 0.81

Autophagy: Directed development. Nat Rev Cancer (2014) 0.81

Metastasis: Influencing bad behaviour. Nat Rev Cancer (2009) 0.80

Epigenetics: Worth another look? Nat Rev Cancer (2011) 0.79

Cell cycle: a WEE pointer. Nat Rev Cancer (2012) 0.79

Cancer stem cells: Tracing clones. Nat Rev Cancer (2012) 0.79

Retinoblastoma: Epigenetic outcome. Nat Rev Cancer (2012) 0.79

Tumorigenesis: Megaphone MYC. Nat Rev Cancer (2012) 0.78

Tumorigenesis: WNT branches out. Nat Rev Cancer (2013) 0.78

Cell polarity: ASPP2 gets a polarity complex. Nat Rev Cancer (2010) 0.78

Tumour heterogeneity: Darwin's finches. Nat Rev Cancer (2012) 0.78

Tumour microenvironment: target practice. Nat Rev Cancer (2011) 0.78

Epigenetics: the long view. Nat Rev Cancer (2013) 0.77

Prognostic models: rising to the challenge. Nat Rev Cancer (2013) 0.77

Epigenetics. Layer by layer. Nat Rev Cancer (2011) 0.77

Lung cancer: A surprising competitor. Nat Rev Cancer (2014) 0.77

Lung cancer: Gastric giveaways. Nat Rev Cancer (2013) 0.77

Anticancer drugs: Targeting menin. Nat Rev Drug Discov (2012) 0.77

Metastasis: Twisting BMI1. Nat Rev Cancer (2010) 0.77

Heterogeneity: A multidimensional overview. Nat Rev Cancer (2013) 0.77

Chromatin remodelling: looking vulnerable. Nat Rev Cancer (2014) 0.77

Metabolism: a TIGAR tale. Nat Rev Cancer (2013) 0.76

Drug resistance: making a point. Nat Rev Cancer (2013) 0.76

Pushing on through. Nat Rev Cancer (2010) 0.76

Systems biology: Lethal weaknesses. Nat Rev Cancer (2011) 0.76

Signalling: REX rules. Nat Rev Cancer (2011) 0.76

Tumorigenesis: Cut here for differentiation. Nat Rev Cancer (2012) 0.76

Epigenetics: Showing a more sensitive side. Nat Rev Cancer (2013) 0.76

Therapeutics: targeting an oncometabolite. Nat Rev Cancer (2013) 0.76

Tumorigenesis. Better by half. Nat Rev Cancer (2012) 0.76

Metastasis: ADORA(2B)tion. Nat Rev Cancer (2013) 0.76

The ARTS of cell death. Nat Rev Cancer (2010) 0.76

Ubiquitylation: Mediation by degradation. Nat Rev Cancer (2013) 0.76

Bladder cancer: seemingly similar. Nat Rev Cancer (2014) 0.76

MicroRNA: lacking in maturity. Nat Rev Cancer (2013) 0.76

Metastasis: Route master. Nat Rev Cancer (2009) 0.76

Tumour suppressors: Selective justice. Nat Rev Cancer (2011) 0.76

Metastasis: Elf represses snail. Nat Rev Cancer (2012) 0.75

DNA damage: "Curiouser and curiouser!" cried Alice. Nat Rev Cancer (2010) 0.75

Leukaemia: 'Gimme shelter'. Nat Rev Cancer (2013) 0.75

Leukaemia: Knowing left from right. Nat Rev Cancer (2013) 0.75

Immunology: In need of a boost? Nat Rev Cancer (2010) 0.75

Metastasis: Going places with VHL. Nat Rev Cancer (2012) 0.75

Genomics: Viral vista. Nat Rev Cancer (2012) 0.75

DNA damage: In at the beginning. Nat Rev Cancer (2013) 0.75

Moving forwards. Nat Rev Cancer (2013) 0.75

DNA damage: The enemy within. Nat Rev Cancer (2012) 0.75

Drug resistance: Time for mediation? Nat Rev Cancer (2012) 0.75

Tumour immunology: Early exposure is inflammatory. Nat Rev Immunol (2011) 0.75

Stem cells: Out for the count. Nat Rev Cancer (2010) 0.75

Mitochondria: Getting together. Nat Rev Cancer (2012) 0.75

Metabolism: Sensitivity to serine starvation. Nat Rev Cancer (2013) 0.75

Melanoma: More horses... Nat Rev Cancer (2013) 0.75

Metabolism: How sweet it is... . Nat Rev Cancer (2013) 0.75

Tumorigenesis: Replicating recurrence. Nat Rev Cancer (2009) 0.75

Finding your inner activator. Nat Rev Cancer (2010) 0.75

DNA damage: Running in parallel. Nat Rev Cancer (2013) 0.75

Stem cells: As directed. Nat Rev Cancer (2013) 0.75

Tumour suppression: Ejector seat. Nat Rev Cancer (2010) 0.75

Immunotherapy: Unlicensed to kill. Nat Rev Cancer (2012) 0.75

Proliferation: Multitasking. Nat Rev Cancer (2012) 0.75

Therapeutics: turnover. Nat Rev Cancer (2013) 0.75

Immunotherapy: Adapt and survive. Nat Rev Cancer (2012) 0.75

Signalling: Regulation and crosstalk. Nat Rev Cancer (2010) 0.75

Metabolism: Nuclear or cytoplasmic? Nat Rev Cancer (2013) 0.75

Medulloblastoma: origins. Nat Rev Cancer (2011) 0.75

Leukaemia: Early changes. Nat Rev Cancer (2012) 0.75

What's a girl to do? Nat Rev Cancer (2013) 0.75

Mitochondria: getting together. Nat Rev Mol Cell Biol (2012) 0.75

Cell death: A2B via p53. Nat Rev Cancer (2013) 0.75

Polarity: In the plane. Nat Rev Cancer (2013) 0.75

Leukaemia: Holding back. Nat Rev Cancer (2013) 0.75

Genomics: A broad brush. Nat Rev Cancer (2010) 0.75

Neuroendocrinology: Housing conditions affect tumour growth. Nat Rev Neurosci (2010) 0.75

Medulloblastoma: origins. Nat Rev Cancer (2011) 0.75

Immunotherapy: Unlicensed to kill. Nat Rev Immunol (2012) 0.75

Anticancer drugs: RAF complexities spark caution. Nat Rev Drug Discov (2010) 0.75

Tumorigenesis: Influencing those around you. Nat Rev Cancer (2012) 0.75

Therapeutics: Disrupting a survival signal. Nat Rev Cancer (2013) 0.75

Tumour suppression: Double act. Nat Rev Cancer (2010) 0.75

Epigenetics: WIP1 creates hush and havoc. Nat Rev Cancer (2013) 0.75

Glioblastoma: histone mutations take the MYCN. Nat Rev Cancer (2013) 0.75

Metastasis: No sympathy? Nat Rev Cancer (2012) 0.75

Signalling: YAP, PTEN and miR-29 size each other up. Nat Rev Cancer (2012) 0.75

Signalling: Keeping TABs on p53. Nat Rev Cancer (2013) 0.75

Macroenvironment: Stimulating resistance. Nat Rev Cancer (2010) 0.75

Therapeutics: Embracing instability. Nat Rev Cancer (2013) 0.75

Cell signalling: Regulation and crosstalk. Nat Rev Mol Cell Biol (2010) 0.75

Stem cells: Self-sufficient. Nat Rev Cancer (2011) 0.75